HLA-DR15

Serology

Serotypes are unknown for the following alleles: DRB1*1506, *1508 to *1516, *1518 to 1522. DRB11517N is a null.

Alleles

Disease associations

DR15 is positively associated Goodpasture syndrome, early age onset multiple sclerosis, pernicious anaemia, sarcoidosis, hypocretin deficiency associated narcolepsy and a predisposition for postmenopausal osteoporosis.

DRB1*1501 is positively associated with Goodpasture syndrome, juvenile rheumatoid arthritis, allergic bronchopulmonary aspergillosis, multiple sclerosis, systemic lupus erythematosus, cervical cancer (human papillomavirus infection), Sjögren syndrome associated with systemic lupus erythematosus, and intermediate uveitis.

DRB1*1502 is associated with systemic lupus erythematosus, systemic sclerosis (SSc) & anti-topoisomerase antibodies.

DRB1*1503 is associated with Chaga's cardiomyopathy, allergic bronchopulmonary aspergillosis, multiple sclerosis, cervical cancer (human papillomavirus infection).

Extended linkage

DRB115:DQA10102:DQB1*0602 haplotype us associated with cervical cancer risk in (human papillomavirus infection)

DRB11502:DQA1????:DQB1*0501 haplotype is associated with systemic lupus erythematosus

Genetic linkage

HLA-DR15 is genetically linked to HLA-DR51 and HLA-DQ6 (HLA-DQ1) serotypes.

References

References

1. [https://www.ebi.ac.uk/imgt/hla/allele.html derived from IMGT/HLA]
2. (2000). "Properties of HLA class II molecules divergently associated with Goodpasture's disease.". Int Immunol.
3. (2000). "HLA-DR15 is associated with lower age at onset in multiple sclerosis.". Annals of Neurology.
4. (1981). "HLA-DR patterns in pernicious anaemia". Br Med J (Clin Res Ed).
5. Bilir M. (2007). "Analysis of HLA antigens in Turkish sarcoidosis patients". South. Med. J..
6. Hong SC. (January 2007). "DQB10301 and DQB10601 modulate narcolepsy susceptibility in Koreans". Hum. Immunol..
7. (2002). "DRB11502-DQB10601-DQA10103 and DRB104-DQB1*0302 in Jewish hypersomnolent patients". Sleep Med..
8. Douroudis K. (2007). "HLA alleles as predisposal factors for postmenopausal osteoporosis in a Greek population". Tissue Antigens.
9. (2005). "Characterization of the T-cell epitope that causes anti-GBM glomerulonephritis". Kidney Int.
10. (1999). "The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity". Kidney Int.
11. (2004). "HLA-DRB1 alleles and HLA-DRB1 shared epitopes are markers for juvenile rheumatoid arthritis subgroups in Colombian mestizos". Hum Immunol.
12. (2004). "An overview of allergic bronchopulmonary aspergillosis with some new insights". Allergy Asthma Proc.
13. (2003). "Genetic and functional studies in multiple sclerosis patients from Martinique attest for a specific and direct role of the HLA-DR locus in the syndrome". Tissue Antigens.
14. (2005). "Genetic contribution of the tumour necrosis factor (TNF) B + 252*2/2 genotype, but not the TNFa,b microsatellite alleles, to systemic lupus erythematosus in Japanese patients". International Journal of Immunogenetics.
15. (1994). "HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity". Nat Genet.
16. (2004). "Sjögren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren's syndrome". Arthritis Rheum.
17. (2015-04-01). "Possession of the HLA-DRB1*1501 Allele and Visual Outcome in Idiopathic Intermediate Uveitis". JAMA Ophthalmology.
18. (2002). "Association of HLA-DRB11502-DQB10501 haplotype with susceptibility to systemic lupus erythematosus in Thais". Tissue Antigens.
19. (1999). "Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody". Arthritis Rheum.
20. (2006). "HLA class II DRB1 polymorphism in Argentinians undergoing chronic Trypanosoma cruzi infection". Ann Clin Biochem.
21. (2000). "Major histocompatibility complex class II polymorphisms and risk of cervical cancer and human papillomavirus infection in Brazilian women". Cancer Epidemiol Biomarkers Prev.